View in EDS

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.

Saved in:
Bibliographic Details
Title: AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.
Authors: Swaih AM; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Talbot S; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Savoca A; Clinical Pharmacology and Safety Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Thorpe H; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Flemington V; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Phillips B; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Colclough N; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., McCoull W; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Radeva V; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Hargreaves D; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Packer MJ; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Felisberto-Rodrigues C; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Thomson C; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Orme JP; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Deane C; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Smith A; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Johnström P; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm 171 76, Sweden., Schou M; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm 171 76, Sweden., McWilliams L; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Davey P; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Enget M; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., O'Neill D; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Cosulich S; Early Oncology Development, Oncology R&D AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Floc'h N; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK. Electronic address: nicolas.floch@astrazeneca.com.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Sep 16; Vol. 6 (9), pp. 102305. Date of Electronic Publication: 2025 Aug 25.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40858103
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Swaih+AM%22">Swaih AM</searchLink>; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Talbot+S%22">Talbot S</searchLink>; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Savoca+A%22">Savoca A</searchLink>; Clinical Pharmacology and Safety Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Thorpe+H%22">Thorpe H</searchLink>; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Flemington+V%22">Flemington V</searchLink>; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Phillips+B%22">Phillips B</searchLink>; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Colclough+N%22">Colclough N</searchLink>; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22McCoull+W%22">McCoull W</searchLink>; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Radeva+V%22">Radeva V</searchLink>; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Hargreaves+D%22">Hargreaves D</searchLink>; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Packer+MJ%22">Packer MJ</searchLink>; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Felisberto-Rodrigues+C%22">Felisberto-Rodrigues C</searchLink>; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Thomson+C%22">Thomson C</searchLink>; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Orme+JP%22">Orme JP</searchLink>; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Deane+C%22">Deane C</searchLink>; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Smith+A%22">Smith A</searchLink>; DMPK, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Johnström+P%22">Johnström P</searchLink>; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm 171 76, Sweden.<br /><searchLink fieldCode="AU" term="%22Schou+M%22">Schou M</searchLink>; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm 171 76, Sweden.<br /><searchLink fieldCode="AU" term="%22McWilliams+L%22">McWilliams L</searchLink>; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Davey+P%22">Davey P</searchLink>; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Enget+M%22">Enget M</searchLink>; Chemistry, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22O'Neill+D%22">O'Neill D</searchLink>; Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Cosulich+S%22">Cosulich S</searchLink>; Early Oncology Development, Oncology R&D AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.<br /><searchLink fieldCode="AU" term="%22Floc'h+N%22">Floc'h N</searchLink>; Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK. Electronic address: nicolas.floch@astrazeneca.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101766894%22">Cell reports. Medicine</searchLink> [Cell Rep Med] 2025 Sep 16; Vol. 6 (9), pp. 102305. <i>Date of Electronic Publication: </i>2025 Aug 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101766894 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3791 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663791%22">26663791 </searchLink><i>NLM ISO Abbreviation: </i>Cell Rep Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40858103
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.xcrm.2025.102305
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102305
    Titles:
      – TitleFull: AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Swaih AM
      – PersonEntity:
          Name:
            NameFull: Talbot S
      – PersonEntity:
          Name:
            NameFull: Savoca A
      – PersonEntity:
          Name:
            NameFull: Thorpe H
      – PersonEntity:
          Name:
            NameFull: Flemington V
      – PersonEntity:
          Name:
            NameFull: Phillips B
      – PersonEntity:
          Name:
            NameFull: Colclough N
      – PersonEntity:
          Name:
            NameFull: McCoull W
      – PersonEntity:
          Name:
            NameFull: Radeva V
      – PersonEntity:
          Name:
            NameFull: Hargreaves D
      – PersonEntity:
          Name:
            NameFull: Packer MJ
      – PersonEntity:
          Name:
            NameFull: Felisberto-Rodrigues C
      – PersonEntity:
          Name:
            NameFull: Thomson C
      – PersonEntity:
          Name:
            NameFull: Orme JP
      – PersonEntity:
          Name:
            NameFull: Deane C
      – PersonEntity:
          Name:
            NameFull: Smith A
      – PersonEntity:
          Name:
            NameFull: Johnström P
      – PersonEntity:
          Name:
            NameFull: Schou M
      – PersonEntity:
          Name:
            NameFull: McWilliams L
      – PersonEntity:
          Name:
            NameFull: Davey P
      – PersonEntity:
          Name:
            NameFull: Enget M
      – PersonEntity:
          Name:
            NameFull: O'Neill D
      – PersonEntity:
          Name:
            NameFull: Cosulich S
      – PersonEntity:
          Name:
            NameFull: Floc'h N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 09
              Text: 2025 Sep 16
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3791
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Cell reports. Medicine
              Type: main
ResultId 1